Stocks to Watch:

Pharmaceutics Latest News: GSK Says Past R&D Shortfalls in China Now Fixed

Wochit 1:06 mins

GlaxoSmithKline said it had faced problems with drug research in China in the past but these shortcomings had now been fixed, following internal changes and the sacking of its China R&D head in June. Britain's biggest drugmaker, which is facing charges of corrupt sales practices in China, said a 2011 internal audit into its Shanghai R&D center had highlighted a number of deficiencies. The British pharmaceutical giant GlaxoSmithKline said that some of its executives might have broken the law in China, the company?s strongest statement yet on a bribery and corruption scandal that has engulfed its China operations. GlaxoSmithKline Chief Executive Andrew Witty will detail what action the drugmaker is taking in response to allegations of bribery against it in China when he presents quarterly results

View Comments